CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
FDA 批准的血液系统恶性肿瘤药物——近十年综述
英文原题：FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.
查看英文原题
FDA-Approved Drugs for Hematological Malignancies-The Last Decade Review.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
血液系统恶性肿瘤，又称血癌，是一组异常细胞在血液、淋巴结或骨髓中生长并持续存在的疾病。新型靶向疗法不断发展，包括小分子抑制剂、单克隆抗体、双特异性T细胞衔接器、抗体偶联药物、重组免疫毒素，最终还包括嵌合抗原受体（CAR）T细胞，改善了血癌患者的临床结局。本综述总结了2011至2021年间美国食品药品监督管理局（FDA）批准用于血液系统恶性肿瘤的52种药物，并将其分为小分子药物和大分子药物。其中40种也获欧洲药品管理局（EMA）批准。我们分析了这些FDA批准药物的结构和作用机制。值得强调的是，靶向药物数量（46种）显著多于化疗药物（6种）。本文重点介绍血液系统恶性肿瘤治疗药物设计方面的近期进展，这些改进使药物更有效、毒性更低。
展开英文摘要原文
Hematological malignancies, also referred to as blood cancers, are a group of diseases involving abnormal cell growth and persisting in the blood, lymph nodes, or bone marrow. The development of new targeted therapies including small molecule inhibitors, monoclonal antibodies, bispecific T cell engagers, antibody-drug conjugates, recombinant immunotoxins, and, finally, Chimeric Antigen Receptor T (CAR-T) cells has improved the clinical outcomes for blood cancers.
In this review, we summarized 52 drugs that were divided into small molecule and macromolecule agents, approved by the Food and Drug Administration (FDA) in the period between 2011 and 2021 for the treatment of hematological malignancies. Forty of them have also been approved by the European Medicines Agency (EMA).
We analyzed the FDA-approved drugs by investigating both their structures and mechanisms of action. It should be emphasized that the number of targeted drugs was significantly higher (46 drugs) than chemotherapy agents (6 drugs).
We highlight recent advances in the design of drugs that are used to treat hematological malignancies, which make them more effective and less toxic.
论文信息
- 作者
- Sochacka-Ćwikła A、Mączyński M、Regiec A
- 单位
- Department of Organic Chemistry and Drug Technology, Faculty of Pharmacy, Wroclaw Medical University, 211A Borowska Street, 50-556 Wroclaw, Poland.Poland
- 文献类型
- 综述
- 期刊
- Cancers2021 Dec 24
- 原文标识
- PubMed 35008250 · DOI 10.3390/cancers14010087
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →